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Carbapenemases increasingly have been reported 
in  Enterobacteriaceae in the past 10 years. Klebsiella 
pneumoniae carbapenemases have been reported in 
the United States and then worldwide, with a marked 
endemicity at least in the United States and Greece. Metallo-
enzymes (Verona integron–encoded metallo-β-lactamase, 
IMP) also have been reported worldwide, with a higher 
prevalence in southern Europe and Asia. Carbapenemases 
of the oxacillinase-48 type have been identiﬁ  ed  mostly 
in Mediterranean and European countries and in India. 
Recent identiﬁ   cation of New Delhi metallo-β-lactamase-1 
producers, originally in the United Kingdom, India, and 
Pakistan and now worldwide, is worrisome. Detection 
of infected patients and carriers with carbapenemase 
producers is necessary for prevention of their spread. 
Identiﬁ   cation of the carbapenemase genes relies mostly 
on molecular techniques, whereas detection of carriers is 
possible by using screening culture media. This strategy 
may help prevent development of nosocomial outbreaks 
caused by carbapenemase producers, particularly K. 
pneumoniae.
E
nterobacteriaceae are inhabitants of the intestinal ﬂ  ora 
and are among the most common human pathogens, 
causing infections such as cystitis and pyelonephritis with 
fever, septicemia, pneumonia, peritonitis, meningitis, and 
device-associated infections. Enterobacteriaceae are the 
source of community- and hospital-acquired infections. 
They have the propensity to spread easily between humans 
(hand carriage, contaminated food and water) and to 
acquire genetic material through horizontal gene transfer, 
mediated mostly by plasmids and transposons.
Since 2000, spread of community-acquired 
enterobacterial isolates (Escherichia coli) that produce 
extended-spectrum  β-lactamases (ESBLs) capable of 
hydrolyzing almost all cephalosporins except carbapenems 
has been reported worldwide (1). It is therefore mandatory 
to maintain the clinical efﬁ  cacy of carbapenems (imipenem, 
ertapenem, meropenem, doripenem), which have 
become antimicrobial drugs of last resort. These agents 
are crucial for preventing and treating life-threatening 
nosocomial infections, which are often associated with 
techniques developed in modern medicine (transplantation, 
hospitalization in an intensive care unit, highly technical 
surgery).
Carbapenem-resistant Enterobacteriaceae have been 
reported worldwide as a consequence largely of acquisition 
of carbapenemase genes (2). The ﬁ  rst  carbapenemase 
producer in Enterobacteriaceae (NmcA) was identiﬁ  ed 
in 1993 (3). Since then, a large variety of carbapenemases 
has been identiﬁ  ed  in  Enterobacteriaceae belonging 
to 3 classes of β-lactamases: the Ambler class A, B, 
and D β-lactamases (2). In addition, rare chromosome-
encoded cephalosporinases (Ambler class C) produced by 
Enterobacteriaceae may possess slight extended activity 
toward carbapenems, but their clinical role remains 
unknown (2,4).
Class A Carbapenemases
A variety of class A carbapenemases have been 
described; some are chromosome encoded (NmcA, Sme, 
IMI-1, SFC-1), and others are plasmid encoded (Klebsiella 
pneumoniae carbapenemases [KPC], IMI-2, GES, 
derivatives), but all effectively hydrolyze carbapenems 
and are partially inhibited by clavulanic acid (2). KPCs 
are the most clinically common enzymes in this group. 
The ﬁ  rst KPC producer (KPC-2 in K. pneumoniae) was 
identiﬁ  ed in 1996 in the eastern United States (5).Within 
a few years, KPC producers had spread globally and have 
been described across the contiguous United States (still 
mostly in eastern coast states) and, in particular, in Puerto 
Rico, Colombia, Greece, Israel, and the People’s Republic 
of China (6,7) (Figure 1). Outbreaks of KPC producers 
also have been reported in many European countries and in 
South America (6,7) (Figure 1).
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KPC producers have been reported, mostly from 
nosocomial K. pneumoniae isolates and to a much lesser 
extent from E. coli (especially in Israel) and from other 
enterobacterial species (6). A single K. pneumoniae clone 
(sequence type [ST]-258) was identiﬁ  ed  extensively 
worldwide, indicating that it may have contributed to the 
spread of the blaKPC genes (8).Within a given geographic 
location, several KPC clones are disseminating that differ 
by multilocus sequence type; additional β-lactamase 
content; and by size, number, and structure of plasmids, 
but the blaKPC genes are associated with a single genetic 
element (transposon Tn4401) (8). Although community-
acquired KPC producers have been reported, they are 
rare, with the exception of isolates from Israel a few 
years ago (6).The level of resistance to carbapenems 
of KPC producers may vary markedly; ertapenem is the 
carbapenem that has the lowest activity (5–7), (Table 1). 
KPC producers are usually multidrug resistant (especially 
to all β-lactams), and therapeutic options for treating KPC-
related infections remain limited (6) (Figure 2, panel A). 
Death rates attributed to infections with KPC producers are 
high (>50%) (9–11).
Class B Metallo-β-Lactamases
Class B metallo-β-lactamases (MBLs) are mostly of the 
Verona integron–encoded metallo-β-lactamase (VIM) and 
IMP types and, more recently, of the New Delhi metallo-
β-lactamase-1 (NDM-1) type (2,12).The  ﬁ  rst  acquired 
MBL, IMP-1, was reported in Serratia marcescens in 
Japan in 1991 (13). Since then, MBLs have been described 
worldwide (2,12) (Figure 3). Endemicity of VIM- and 
IMP-type enzymes has been reported in Greece, Taiwan, 
and Japan (2,12), although outbreaks and single reports 
of VIM and IMP producers have been reported in many 
other countries (Figure 3). These enzymes hydrolyze all 
β-lactams except aztreonam (12).Their activity is inhibited 
by EDTA but not by clavulanic acid (12). Most MBL 
producers are hospital acquired and multidrug-resistant K. 
pneumoniae (2,12). Resistance levels to carbapenems of 
MBL producers may vary (Table 1). Death rates associated 
with MBL producers range from 18% to 67% (14).
Discovered in 2008 in Sweden from an Indian 
patient hospitalized previously in New Delhi (15), NDM-
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Figure 1. A) Worldwide geographic distribution of Klebsiella pneumoniae carbapenemase (KPC) producers. Gray shading indicates 
regions shown separately: B) distribution in the United States; C) distribution in Europe; D) distribution in China.
Table 1. MIC range of carbapenems for Enterobacteriaceae that 
produce several types of carbapenemases* 
Carbapenemase 
MIC, mg/L 
Imipenem Meropenem Ertapenem 
KPC 0.5–>64  1–>64  0.5–>64 
Metallo ȕ-lactamases† 0.5–>64  0.25–>64  0.5–>64 
OXA-48 type  1–>64  0.5–>64  0.25–>64 
*KPC, Klebsiella pneumoniae carbapenemase; OXA-48, oxacillinase-48. 
†Including New Delhi metallo-ȕ-lactamase-1. Carbapenemase-producing Enterobacteriaceae
1–positive  Enterobacteriaceae are now the focus of 
worldwide attention (15–17). Since mid-August 2010, 
NDM-1 producers have been identiﬁ  ed on all continents 
except in Central and South America with, in most of 
the cases, a direct link with the Indian subcontinent (17) 
(Figure 4). Few cases have been reported from the United 
States and Canada (17). Recent ﬁ  ndings suggest that the 
Balkan states and the Middle East may act as secondary 
reservoirs of NDM-1 producers (17) (Figure 4).
In contrast to several other carbapenemase genes, 
the  blaNDM-1 gene is not associated with a single clone 
but rather with nonclonally related isolates and species 
(16,17). It has been identiﬁ  ed mostly in E. coli and K. 
pneumoniae and to a lesser extent in other enterobacterial 
species (16,17). The level of resistance to carbapenems of 
NDM-1 producers may vary (Table 1). Plasmids carrying 
the blaNDM-1 gene are diverse and can harbor a high number 
of resistance genes associated with other carbapenemase 
genes (oxacillinase-48 [OXA-48] types, VIM types), 
plasmid-mediated cephalosporinase genes, ESBL genes, 
aminoglycoside resistance genes (16S RNA methylases), 
macrolide resistance genes (esterase), rifampin (rifampin-
modifying enzymes) and sulfamethoxazole resistance 
genes as a source of multidrug resistance and pandrug 
resistance (16,17) (Figure 2, panel B). The association of 
such a high number of resistance genes in single isolates has 
been rarely observed, even among the other carbapenemase 
producers. Many NDM-1 producers remain susceptible 
only to tigecycline, colistin (Figure 2, panel B), and to a 
lesser extent fosfomycin (16,17).
Compared with other carbapenemases, NDM-1 has 
several characteristics that are deeply disconcerting for 
public health worldwide. These characteristics are 1) 
occurrence of the blaNDM-1 gene not in a single species but in 
many unrelated species and its spread in the environment, at 
least in the Indian subcontinent (18); 2) frequent acquisition 
by K. pneumoniae, a typical nosocomial pathogen, but also 
by E. coli that is by far the main (community-acquired) 
human pathogen; and 3) size of the reservoir—the Indian 
subcontinent has >1.4 billion persons. In certain areas 
in Pakistan, <20% of the population may carry NDM-1 
producers (P. Nordmann, unpub. data).
Of particular concern, NDM-1 has been identiﬁ  ed in 
E. coli ST-type 131 as a source of community-acquired 
infection (19), an ST type that is known to mobilize 
efﬁ   ciently the ESBL CTX-M-15 worldwide (20).  E. 
coli is the most common cause of diarrhea in children in 
India. Therefore, this organism may increase the risk of 
drug-resistant strains being released into the environment 
and further spread among humans. Accordingly, NDM-1 
producers have been recently identiﬁ   ed in tap and 
environmental water in New Delhi, among many unrelated 
gram-negative species (18).
Class D Enzymes of the OXA-48 Type
The  ﬁ  rst  identiﬁ   ed OXA-48 producer was from a 
K. pneumoniae strain isolated in Turkey in 2003 (21). 
Since then, OXA-48 producers have been extensively 
reported from Turkey as a source of nosocomial outbreaks 
(22–26). Their worldwide distribution now includes 
countries in Europe, in the southern and eastern part of the 
Mediterranean Sea, and Africa (21–26) (Figure 5). OXA-48 
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Figure 2. Disk diffusion antibacterial drug susceptibility testing of A) 
Klebsiella pneumoniae carbapenemase-2 (KPC-2)–, B) New Delhi 
metallo-β-lactamase-1 (NDM-1)–, and C) oxacillinase-48 (OXA-48)–
producing K. pneumoniae clinical isolates. Clinical isolates producing 
KPC-2 and OXA-48 do not co-produce other extended-spectrum 
β-lactamase, but the isolate producing NDM-1 co-produces the 
extended-spectrum β-lactamase CTX-M-15. Wild-type susceptibility 
to β-lactams of K. pneumoniae includes resistance to amoxicillin, 
ticarcillin, and reduced susceptibility to piperacillin and cefalotin 
(data not shown).TZP, piperacillin/tazobactam; PIP, piperacillin; 
TIC, ticarcillin; AMX, amoxicillin; ETP, ertapenem; TCC, ticarcillin/
clavulanic acid; CAZ, ceftazidime; CF, cefalotin; FOX, cefoxitin; IMP, 
imipenem; AMC, amoxicillin/clavulanic acid; CTX, cefotaxime; CXM, 
cefuroxime; MEM, meropenem; ATM, aztreonam; FEP, cefepime; 
CIP, ciproﬂ  oxacin; CS, colistin; NET, netilmicin; RA, rifampin; OFX, 
oﬂ   oxacin; TE, tetracycline; C, chloramphenicol; TM, tobramycin; 
NOR, norﬂ   oxacin; TGC, tigecycline; SXT, sulfamethoxazole/
trimethoprim; AN, amikacin; FT, nitrofurantoin; FOS, fosfomycin; 
SSS, sulfamethoxazole; GM gentamicin. PERSPECTIVE
producers have not been reported from the United States 
and Canada. A point mutant analog of OXA-48, OXA-181, 
with similar carbapenemase activity, has been identiﬁ  ed in 
strains from India or of Indian origin (27,28). There is an 
increasing trend of identiﬁ  cation of OXA-48 producers in 
countries such as France, Germany, Spain, the Netherlands, 
and the United Kingdom through transfer of hospitalized 
patients from disease-endemic areas that are the source of 
hospital outbreaks (Figure 5).
Several OXA-48–producing clones have been 
identiﬁ   ed, and dissemination of this resistance trait is 
associated with a 62.5-kb plasmid (previously identiﬁ  ed 
as a plasmid of ≈70 kb) (22). OXA-48/OXA-181 are 
peculiar because they weakly hydrolyze carbapenems and 
broad-spectrum cephalosporins, such as ceftazidime, and 
aztreonam (21,27), (Figure 2, panel C). Their activity is 
not inhibited by EDTA or clavulanic acid (resistance to 
amoxicillin/clavulanic acid; Figure 2, panel C). Although 
reported in various enterobacterial species, OXA-48 
producers are mostly identiﬁ  ed in K. pneumoniae and E. 
coli, and the level of resistance to carbapenems is usually 
higher when ESBL and permeability defects are associated 
(22–28), (Table 1). The OXA-48–type producers are likely 
the most difﬁ  cult carbapenemase producers to be identiﬁ  ed. 
Thus, their true prevalence could be underestimated. The 
attributed mortality rate from infections with OXA-48 
producers is unknown.
Identiﬁ  cation of Carbapenemase Producers
The detection of carbapenemase producers in clinical 
infections is based ﬁ   rst on susceptibility testing results 
obtained by disk diffusion or by automated systems (29). The 
Clinical and Laboratory Standards Institute (CLSI; Wayne, 
PA, USA) breakpoints of carbapenems have been lowered 
substantially in 2010 for a better detection of carbapenem-
resistant isolates and carbapenemase producers (Table 2). 
The CLSI breakpoints of carbapenems are now lower than 
those of the European guidelines (Table 2). Applying the 
CLSI breakpoints is all that is needed for making treatment 
decisions according to CLSI recommendations. Special 
tests for carbapenemase detection are recommended for 
epidemiology and infection issues.
However, low-level resistance and even susceptibility 
to carbapenems have been observed for producers of any 
type of carbapenemases (Table 1). We believe, as do others 
(30), that the search for carbapenemase producers should 
be made for any enterobacterial isolates with decreased 
susceptibility to carbapenems. Our opinion is based on 
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Figure 3. Worldwide (A) and European (B) 
geographic distribution of Verona integron–
encoded metallo-β-lactamase (VIM) and 
IMP enterobacterial producers.Carbapenemase-producing Enterobacteriaceae
the paucity of clinical experience for treating infections 
caused by carbapenemase producers, on the unknown level 
of carbapenemase production in the site of the infection 
in vivo, and on the possibility of selecting in vivo for 
strains with increased levels of resistance to carbapenems 
and additional mechanisms of carbapenem resistance 
(carbapenemase, outer-membrane permeability defects).
Speciﬁ   c tests may help identify phenotypically a 
carbapenemase activity. The modiﬁ  ed Hodge test based on 
in vivo production of carbapenemase has been suggested for 
detecting carbapenemase producers (29,31,32). However, 
this test is time consuming and may lack speciﬁ  city (high-
level AmpC producers) and sensitivity (weak detection 
of NDM producers) (27,29). This test may be useful for 
detecting KPC and OXA-48 producers (P. Nordmann, 
unpub. data). Boronic acid–based inhibition testing is 
reported to be speciﬁ  c for KPC detection in K. pneumoniae 
when performed with imipenem or meropenem but not with 
ertapenem if corresponding isolates co-produce a plasmid-
mediated AmpC β-lactamase (29,30). The Etest MBL 
strip (bioMérieux, Solna, Sweden) is one of the methods 
advocated for detecting MBL producers on the basis of 
inhibition of MBL activity by EDTA (12). The Etest MBL, 
using imipenem and imipenem/EDTA, is efﬁ  cient  for 
detection of MBL producers with high resistance (12), but 
may be deﬁ  cient for detecting MBL producers with low 
resistance to imipenem. No inhibition test is available for 
detection of OXA-48/OXA-181 producers.
Spectrophotometric assay is needed for detecting 
carbapenemase activity. However, this assay is time 
consuming, requires speciﬁ  c training, and does not easily 
discriminate between different types of carbapenemases.
The standard for identiﬁ   cation of carbapenemases 
is based on use of molecular techniques, mostly 
PCR (29,33). A list of primers of the most prevalent 
carbapenemase genes identiﬁ  ed  in  Enterobacteriaceae 
is shown in Table 3 (34). Standard conditions may be 
used for PCR-based detection (34). PCR performed on 
colonies may give results within 4–6 hours with excellent 
sensibility and speciﬁ   city. Similarly, other molecular 
techniques, such as the Check-Points DNA technology, 
are useful for this purpose (35). Sequencing of PCR 
products may be of interest mostly for epidemiologic 
purposes. The main disadvantages of molecular-based 
technologies for detection of carbapenemases are their 
cost, the requirement of trained personal, and the absence 
of detection of any novel carbapenemase gene. Thus, there 
is an urgent need for an inexpensive, rapid, sensitive, and 
speciﬁ  c test for detection of carbapenemase activity.
The prevention of spread of carbapenemase producers 
relies on early detection of carriers (29,33). Patients who 
undergo screening should include patients who were 
hospitalized while abroad and then transferred to another 
country, and patients at risk (e.g., patients in intensive care 
units, transplant patients, immunocompromised patients). 
Screened patients should be kept in strict isolation before 
obtaining results of the screening (at least 24–48 hours). 
Because the reservoir of carbapenemase producers remains 
the intestinal ﬂ  ora, fecal and rectal swab specimens are 
adequate for performing this screening. Those specimens 
may be plated directly on screening media.
There is no universal screening medium able to detect 
all types of carbapenemase producers with high sensitivity 
and high speciﬁ   city, however. Agar plates containing 
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Figure 4. Geographic distribution of New 
Delhi metallo-β-lactamase-1 producers, 
July 15, 2011. Star size indicates 
number of cases reported. Red stars 
indicate infections traced back to India, 
Pakistan, or Bangladesh; green stars 
indicate infections traced back to the 
Balkan states or the Middle East; and 
black stars indicate contaminations of 
unknown origin. (Most of the information 
corresponds to published data; other 
data are from P. Nordmann.)PERSPECTIVE
imipenem at a concentration of 1 mg/L have been 
proposed for screening only KPC producers (36). We have 
demonstrated that a culture medium designed to screen 
for ESBL producers (ChromID ESBL; bioMérieux, La-
Balme-Les-Grotte, France) may be used also for screening 
carbapenemase producers. Although this medium may 
lack speciﬁ   city (co-detection of ESBL producers), its 
sensitivity is higher than a culture medium designed 
to screen for carbapenemase producers (CHROMagar 
KPC; CHROMagar, Paris, France) (33,37). The main 
problem remains detection of OXA-48 producers that are 
susceptible to cephalosporins and have low-level resistance 
to carbapenems when not co-producing an ESBL (Figure 
2, panel C) (37). None of these culture media detect those 
OXA-48 producers (37).
After this screening procedure, carbapenemase 
producers may be identiﬁ  ed according to the techniques 
described above (antibacterial drug susceptibility testing, 
molecular techniques). Recently, PCR-based techniques 
performed directly on fecal specimens have been proposed 
for detection of KPC and NDM-1 producers.
Conclusions
Carbapenemase producers in Enterobacteriaceae are 
not the source of speciﬁ  c types of clinical infections. The role 
of these bacteria is related to the difﬁ  cult-to-treat infections 
rather than to expression of speciﬁ  c virulence traits.
We believe we are now at the edge of 2 concomitant 
epidemics of carbapenemase producers worldwide. The 
ﬁ  rst epidemic will be caused mainly by carbapenemase 
producers in E. coli as a source of community-acquired 
infections. These carbapenemases are thus far primarily 
of the NDM and of the OXA-48 types. A few published 
reports of community-acquired infections caused by 
carbapenemase producers are available, but it is more 
likely that the numbers of cases in disease-endemic areas 
are already high. The example of the spread of ESBL 
producers in the community within the past 10 years shows 
us that a high rate of carbapenemase producers in E. coli 
may be reached rapidly worldwide. As opposed to a viral 
epidemic, such as pandemic (H1N1) 2009, the epidemic 
of carbapenemase producers cannot stop spontaneously. 
Such community-based outbreaks will be difﬁ  cult  to 
control. Modulation of the factors that enhance spread of 
carbapenemase producers in the community is difﬁ  cult 
because these factors are multiple and are associated 
with lack of hygiene, overuse and over-the-counter use 
of antibacterial drugs, and increased worldwide travel. In 
addition, many carbapenemase producers carry unrelated 
drug-resistance determinants. Therefore, selection pressure 
with structurally unrelated antibacterial drugs (not only 
β-lactams) may contribute to their spread.
We cannot predict either the speed of diffusion of 
those carbapenemase producers in the community or 
their prevalence at a steady state (5%–50%?). The actual 
prevalence of carbapenemase producers is still unknown 
because many countries that are likely to be their main 
reservoirs have not established any search protocol for 
their detection. The prevalence may substantially differ, 
depending on the country, as known with the current 
prevalence rate of ESBL producers in E. coli. The 
prevalence is estimated to be 3%–5% in France and >80% 
in India (38).
The second epidemic will likely be caused mainly by 
nosocomial carbapenemase producers in K. pneumoniae of 
all types (KPC, IMP, VIM, NDM, and OXA-48). It is likely 
that in certain countries high rates of different types of 
carbapenemase producers may already exist, for example, 
in Greece (VIM and KPC) and in the Indian subcontinent 
(NDM, KPC, OXA-181). K. pneumoniae will play a major 
role because it has been repeatedly identiﬁ  ed to be the most 
common enterobacterial species for spreading ESBL genes 
in health care facilities during the past 30 years. It may 
play the same role for spreading carbapenemase producers 
in patients with identical risk factors (patients receiving 
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Figure 5. Geographic distribution of oxacillinase-48 (OXA-48) type 
producers.
Table 2. Breakpoint values (MIC, mg/L) for carbapenems 
according to guidelines in Europe (EUCAST) and the United 




Ertapenem <0.5 >1 <0.25 >1
Imipenem <2> 8 < 1> 4
Meropenem <2> 8 < 1> 4
*EUCAST, European Committee on Antimicrobial Susceptibility Testing 
(www.eucast.org/clinical_breakpoints); CLSI, Clinical and Laboratory 
Standards Institute; S, sensitive; R, resistant. Carbapenemase-producing Enterobacteriaceae
broad-spectrum antibiotherapy, patients in intensive care 
units, immunocompromised patients, transplant patients, 
surgical patients). Early identiﬁ  cation of carbapenemase 
producers in clinical infections, at the carriage state, or 
both, is therefore mandatory to prevent development of 
those hospital-based outbreaks. We believe we still can 
efﬁ  ciently prevent emergence of hospital-based outbreaks 
of carbapenemase producers. A similar strategy has 
been implemented in northern European countries for 
containment of hospital-acquired methicillin-resistant 
Staphylococcus aureus, which has been useful.
The dearth of novel antibacterial drugs in the pipeline 
means that we must conserve the efﬁ   cacy of existing 
antibacterial drugs as much as possible. Carbapenemase 
producers in Enterobacteriaceae are different from other 
multidrug-resistant bacteria in that they are susceptible to 
few (if any) antibacterial drugs (39).
No vaccines are readily available for preventing 
infections with carbapenemase producers. This ﬁ  nding is 
particularly true for E. coli, which is part of the human 
intestinal  ﬂ   ora. Therefore, everything must be done to 
prevent infections as common as pyelonephritis from 
becoming life threatening because of the lack of any 
effective treatment.
Acknowledgments
We thank Sandrine Barnabeu, Amélie Carrër, and Gaëlle 
Cuzon for collecting much of the data presented in this review.
This work was funded by grants from the National Institute 
of Health and Medical Research (INSERM) research unit 914 
and by the Ministère de l’Education Nationale et de la Recherche 
(UPRES-EA3539), Université Paris XI, Paris, France. 
Dr Nordmann is professor of medical microbiology at 
South-Paris Medical School, chief of the Department of Clinical 
Microbiology at Bicêtre Hospital, and head of National Institute 
of Health and Medical Research (INSERM) research unit 914, 
Emerging Antibiotic Resistance, Le Kremlin-Bicêtre, France. His 
research focuses on molecular mechanisms of antibiotic resistance 
and their clinical implication.
References
  1.   Pitout JD, Laupland KB. Extended-spectrum β-lactamase–produc-
ing Enterobacteriaceae: an emerging public-health concern. Lancet 
Infect Dis. 2008;8:159–66. doi:10.1016/S1473-3099(08)70041-0
  2.   Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. 
Clin Microbiol Rev. 2007;20:440–58. doi:10.1128/CMR.00001-07
  3.   Naas T, Nordmann P. Analysis of a carbapenem-hydrolyzing class 
A  β-lactamase from Enterobacter cloacae and of its LysR-type 
regulatory protein. Proc Natl Acad Sci U S A. 1994;91:7693–7. 
doi:10.1073/pnas.91.16.7693
  4.   Giske CG, Sundsfjord AS, Kahlmeter G, Woodford N, Nordmann 
P, Paterson DL, et al. Redeﬁ  ning extended-spectrum β-lactamase: 
balancing science and clinical need. J Antimicrob Chemother. 
2009;63:1–4. doi:10.1093/jac/dkn444
  5.   Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle 
JW, Steward CD, et al. Novel carbapenem-hydrolyzing β-lactamase 
KPC-1 from a carbapenem-resistant strain of Klebsiella pneumoni-
ae. Antimicrob Agents Chemother. 2001;45:1151–61. doi:10.1128/
AAC.45.4.1151-1161.2001
  6.   Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneu-
moniae carbapenemase-producing bacteria. Lancet Infect Dis. 
2009;9:228–36. doi:10.1016/S1473-3099(09)70054-4
  7.   Navon-Venezia S, Leavitt A, Schwaber MJ, Rasheed JK, Srinivasan 
A, Patel JB, et al. First report on a hyperepidemic clone of KPC-
3–producing Klebsiella pneumoniae in Israel genetically related to 
a strain causing outbreaks in the United States. Antimicrob Agents 
Chemother. 2009;53:818–20. doi:10.1128/AAC.00987-08
  8.   Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y, 
et al. Worldwide diversity of Klebsiella pneumoniae that produce 
β-lactamase  blaKPC-2 gene. Emerg Infect Dis. 2010;16:1349–56. 
doi:10.3201/eid1609.091389
  9.   Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ 
R, et al. Attributable mortality rate for carbapenem-resistant Kleb-
siella pneumoniae bacteremia. Infect Control Hosp Epidemiol. 
2009;30:972–6. doi:10.1086/605922
10.   Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of 
carbapenem-resistant Klebsiella pneumoniae infection and the im-
pact of antimicrobial and adjunctive therapies. Infect Control Hosp 
Epidemiol. 2008;29:1099–106. doi:10.1086/592412
11.    Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, 
Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Kleb-
siella pneumoniae acquisition among hospitalized adults and ef-
fect of acquisition on mortality. Antimicrob Agents Chemother. 
2008;52:1028–33. doi:10.1128/AAC.01020-07
12.   Walsh TR, Toleman MA, Poirel L, Nordmannn P. Metallo-β-
lactamases: the quiet before the storm? Clin Microbiol Rev. 
2005;18:306–25. doi:10.1128/CMR.18.2.306-325.2005
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 10, October 2011  1797
Table 3. Oligonucleotides used for screening of main carbapenemase genes in Enterobacteriaceae* 
Primer Sequence,  5ƍ o 3ƍ  Gene  Product size, bp 
IMP-F GGAATAGAGTGGCTTAAYTC  blaIMP 232 
IMP-R TCGGTTTAAYAAAACAACCACC     
VIM-F GATGGTGTTTGGTCGCATA  blaVIM 390 
VIM-R CGAATGCGCAGCACCAG     
OXA-48-F GCGTGGTTAAGGATGAACAC  blaOXA-48 438 
OXA-48-R CATCAAGTTCAACCCAACCG    
NDM-F GGTTTGGCGATCTGGTTTTC  blaNDM 621 
NDM-R CGGAATGGCTCATCACGATC     
KPC-Fm CGTCTAGTTCTGCTGTCTTG  blaKPC 798 
KPC-Rm CTTGTCATCCTTGTTAGGCG     
*A detailed technique for PCR amplification has been reported by Poirel et al. (34). VIM, Verona integron–encoded metallo-ȕ-lactamase; OXA, 
oxacillinase; NDM, New Delhi metallo-ȕ-lactamase-1; KPC, Klebsiella pneumoniae carbapenemase. PERSPECTIVE
13.   Ito H, Arakawa Y, Ohsuka S, Wacharotayankun R, Kato N, Ohta M. 
Plasmid-mediated dissemination of the metallo-β-lactamase gene 
blaIMP among clinically isolated strains of Serratia marcescens. An-
timicrob Agents Chemother. 1995;39:824–9.
14.   Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E, 
Skoutelis A, et al. Prospective observational study of the impact of 
VIM-1 metallo-β-lactamase on the outcome of patients with Kleb-
siella pneumoniae bloodstream infections. Antimicrob Agents Che-
mother. 2009;53:1868–73.  doi:10.1128/AAC.00782-08
15.   Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, 
et al. Characterization of a new metallo-β-lactamase gene, blaNDM-1, 
and a novel erythromycin esterase gene carried on a unique genetic 
structure in Klebsiella pneumoniae sequence type 14 from India. 
Antimicrob Agents Chemother. 2009;53:5046–54. doi:10.1128/
AAC.00774-09
16.    Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, 
Balakrishnan R, et al. Emergence of a new antibiotic resistance 
mechanism in India, Pakistan, and the UK: a molecular, biological, 
and epidemiological study. Lancet Infect Dis. 2010;10:597–602. 
doi:10.1016/S1473-3099(10)70143-2
17.   Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-
spectrum β-lactam resistance due to NDM-1 herald the end of the 
antibiotic era for treatment of infections caused by Gram-negative 
bacteria? J Antimicrob Chemother. 2011;66:689–92. doi:10.1093/
jac/dkq520
18.   Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination 
of NDM-1 positive bacteria in the New Delhi environment and its 
implications for human health: an environmental point prevalence 
study. Lancet Infect Dis. 2011;11:355–62.
19.   Poirel L, Hombrouk-Alet C, Freneaux C, Bernabeu S, Nordmann P. 
Global spread of New Delhi metallo-β-lactamase 1. Lancet Infect 
Dis. 2010;10:832. doi:10.1016/S1473-3099(10)70279-6
20.   Coque TM, Novais A, Carattoli A, Poirel L, Pitout J, Peixe L, et al. 
Dissemination of clonally related Escherichia coli strains express-
ing extended-spectrum β-lactamase CTX-M-15. Emerg Infect Dis. 
2008;14:195–200. doi:10.3201/eid1402.070350
21.   Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacil-
linase-mediated resistance to imipenem in Klebsiella pneumoniae. 
Antimicrob Agents Chemother. 2004;48:15–22. doi:10.1128/
AAC.48.1.15-22.2004
22.   Carrër A, Poirel L, Yilmaz M, Akan OA, Feriha C, Cuzon G, et 
al. Spread of OXA-48–encoding plasmid in Turkey and beyond. 
Antimicrob Agents Chemother. 2010;54:1369–73. doi:10.1128/
AAC.01312-09
23.   Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. Outbreak 
of OXA-48–positive carbapenem-resistant Klebsiella pneumoniae 
isolates in France. Antimicrob Agents Chemother. 2011;55:2420–3. 
doi:10.1128/AAC.01452-10
24.   Moquet O, Bouchiat C, Kinana A, Seck A, Arouna O, Bercion R, et 
al. Class D OXA-48 carbapenemase in multidrug-resistant entero-
bacteria, Senegal. Emerg Infect Dis. 2011;17:143–4. doi:10.3201/
eid1701.100224
25.   Benouda A, Touzani O, Khairallah MT, Araj GF, Matar GM. First 
detection of oxacillinase-mediated resistance to carbapenems in 
Klebsiella pneumoniae from Morocco. Ann Trop Med Parasitol. 
2010;104:327–30. doi:10.1179/136485910X12743554760108
26.   Poirel L, Ros A, Carrër A, Fortineau N, Carricajo A, Berthelot P, 
et al. Cross-border transmission of OXA-48–producing Entero-
bacter cloacae from Morocco to France. J Antimicrob Chemother. 
2011;66:1181–2. doi:10.1093/jac/dkr023
27.    Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, 
Mendes RE. Early dissemination of NDM-1– and OXA-181–pro-
ducing Enterobacteriaceae in Indian hospitals: report from the SEN-
TRY Antimicrobial Surveillance Program, 2006–2007. Antimicrob 
Agents Chemother. 2011;55:1274–8. doi:10.1128/AAC.01497-10
28.   Kalpoe JS, Al Naiemi N, Poirel L, Nordmann P. Detection of an 
Ambler class D OXA-48–type β-lactamase in a Klebsiella pneu-
moniae strain in The Netherlands. J Med Microbiol. 2011;60:677–8. 
doi:10.1099/jmm.0.028308-0
29.   Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniad-
kowski M, et al. Acquired carbapenemases in Gram-negative bac-
terial pathogens: detection and surveillance issues. Clin Microbiol 
Infect. 2010;16:112–22. doi:10.1111/j.1469-0691.2009.03116.x
30.   Thomson KS. Extended-spectrum β-lactamase, AmpC and carbapen-
emase issues. J Clin Microbiol. 2010;48:1019–25. doi:10.1128/
JCM.00219-10
31.   Centers for Disease Control and Prevention. Guidance for control of 
infections with carbapenem-resistant or carbapenemase-producing 
Enterobacteriaceae in acute care facilities. MMWR Morb Mortal 
Wkly Rep. 2009;58:256–60.
32.   Galani I, Rekatsina PD, Hatzaki D, Plachouras D, Souli M, Gia-
marellou H. Evaluation of different laboratory tests for the detection 
of metallo-β-lactamase production in Enterobacteriaceae. J Antimi-
crob Chemother. 2008;61:548–53. doi:10.1093/jac/dkm535
33.   Nordmann P, Poirel L, Carrër A, Toleman MA, Walsh TR. How 
to detect NDM-1 producers. J Clin Microbiol. 2011;49:718–21. 
doi:10.1128/JCM.01773-10
34.   Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for 
detection of acquired carbapenemase genes. Diagn Microbiol Infect 
Dis. 2011;70:119–23. doi:10.1016/j.diagmicrobio.2010.12.002
35.   Naas T, Cuzon G, Bogaerts P, Glupczynski Y, Nordmann P. Evalua-
tion of a DNA microarray (Check-MDR CT102) for rapid detection 
of TEM, SHV, and CTX-M extended-spectrum β-lactamases and of 
KPC, OXA-48, VIM, IMP, and NDM-1 carbapenemases. J Clin Mi-
crobiol. 2011;49:1608–13. doi:10.1128/JCM.02607-10
36.   Adler A, Navon-Venezia S, Moran-Gilad J, Marcos E, Schwartz 
D, Carmeli Y. Laboratory and clinical evaluation of screening agar 
plates for the detection of carbapenem-resistant enterobacteriaceae 
from surveillance rectal swabs. J Clin Microbiol. 2011;49:2239–42. 
doi:10.1128/JCM.02566-10
37.   Carrër A, Fortineau N, Nordmann P. Use of ChromID ESBL me-
dium for detecting carbapenemase-producing Enterobacteriaceae. J 
Clin Microbiol. 2010;48:1913–4. doi:10.1128/JCM.02277-09
38.   Jean SS, Hsueh PR. High burden of antibimicrobial resistance in Asia. 
Int J Antimicrob Agents. 2011;37:291–5. doi:10.1016/j.ijantimicag.
2011.01.009
39.   Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic op-
tions with Enterobacteriaceae producing carbapenem-hydrolyzing 
enzymes. Future Microbiol. 2011;6:653–6. doi:10.2217/fmb.11.49
Address for correspondence: Patrice Nordmann, Service de Bactériologie-
Virologie, Hôpital de Bicêtre, 78 Rue du Général Leclerc, 94275 
K-Bicêtre, France; email: nordmann.patrice@bct.aphp.fr
1798  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 10, October 2011
The opinions expressed by authors contributing to this 
journal do not necessarily reﬂ  ect the opinions of the Centers for 
Disease Control and Prevention or the institutions with which 
the authors are afﬁ  liated.
Search past issues of EID at www.cdc.gov/eid